Copyright
©The Author(s) 2019.
World J Stem Cells. Apr 26, 2019; 11(4): 212-221
Published online Apr 26, 2019. doi: 10.4252/wjsc.v11.i4.212
Published online Apr 26, 2019. doi: 10.4252/wjsc.v11.i4.212
Indication | Level of recommendation | Level of evidence |
Systemic sclerosis | Clinical opportunity: a careful evaluation of the benefit / risk ratio is required | I |
Multiple sclerosis | II | |
Chronic inflammatory demyelinating polyneuropathy | II | |
Myasthenia gravis | II | |
Crohn's disease | II | |
Systemic lupus erythematosus | II | |
Rheumatoid arthritis | II | |
Juvenile idiopathic arthritis | II | |
Autoimmune cytopenias | II | |
Polymyositis/dermatomyositis | III | |
Vasculitides | III | |
Neuromyelitis optica | III | |
Paraneoplastic neurological symptoms | III | |
Type 1 diabetes mellitus | Under construction | III |
Refractory celiac disease | III |
- Citation: Műzes G, Sipos F. Issues and opportunities of stem cell therapy in autoimmune diseases. World J Stem Cells 2019; 11(4): 212-221
- URL: https://www.wjgnet.com/1948-0210/full/v11/i4/212.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v11.i4.212